OncoMatch/Clinical Trials/NCT07217704
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Is NCT07217704 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies [18F]FAPI-74 PET/CT for esophageal cancer.
Treatment: [18F]FAPI-74 PET/CT — This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standardized administration protocol and dose, participants will undergo \[¹⁸F\]FAPI-74 PET/CT screening. SOC procedures and interventions will be captured during 3 months +/-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \[¹⁸F\]FAPI-74 PET/CT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow up. The participants will be followed-up for safety for 24 to 72 hours after the dose of \[¹⁸F\]FAPI-74 PET/CT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Gastric Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: treatment for curative intent of Gastroesophageal cancers
Treatment, including chemotherapy, radiation, immunotherapy or surgery for curative intent of Gastroesophageal cancers
Lab requirements
Kidney function
gfr < 30 ml/min [excluded]
Liver function
t. bili >1.5x uln or alk phos, alt, or ast >5x uln [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Helios CR Inc./RadNet · Cerritos, California
- Hoag Memorial Hospital · Irvine, California
- UCLA · Los Angeles, California
- Moffit Cancer Center · Tampa, Florida
- Indiana University Health University Hospital · Indianapolis, Indiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07217704 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior treatment for curative intent of Gastroesophageal cancers disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages